[Efficacy, safety, and pharmaco-economical aspects of the therapy for dyslipidemia with brand-name and generic statins]

Ter Arkh. 2003;75(12):47-50.
[Article in Russian]

Abstract

Aim: To compare clinical, cost-effect efficacies and safety of simvastatin Zokor and generic Vasilip in correction of dislipoproteinemia in patients with ischemic heart disease.

Material and methods: The original statin Zokor and generic statin Vasilip were given for 8 weeks in a dose 20 mg/day.

Results: Vasilip and Zokor demonstrated similar hypolipidemic efficacy and safety, but Vasilip administration was more cost-effective.

Conclusion: Simvastatin Vasilip is recommended for wider use in clinical practice because it is clinically and cost effective.

Publication types

  • Clinical Trial
  • Comparative Study
  • English Abstract

MeSH terms

  • Cholesterol / blood
  • Drug Costs*
  • Drugs, Generic* / adverse effects
  • Drugs, Generic* / economics
  • Drugs, Generic* / therapeutic use
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / economics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Hyperlipidemias / blood
  • Hyperlipidemias / diet therapy
  • Hyperlipidemias / drug therapy*
  • Lipoproteins, HDL / blood
  • Lipoproteins, LDL / blood
  • Male
  • Middle Aged
  • Simvastatin* / adverse effects
  • Simvastatin* / economics
  • Simvastatin* / therapeutic use
  • Triglycerides / blood

Substances

  • Drugs, Generic
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Triglycerides
  • Cholesterol
  • Simvastatin